Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

3

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Iron

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

2011

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Iron overload

1

Thalassemia syndrome

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

University of Essex

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

EPA CompTox

4

FDA UNII

4

PUBCHEM

4

WIKIPEDIA

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

VARIOUS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ALL OTHER THERAPEUTIC PRODUCTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ALL OTHER THERAPEUTIC PRODUCTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Iron chelating agents

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DEFERIPRONE

2BTY8KH53L

Export Data
Search for Structure

Status:

US Approved Rx (2020)

First approved in 2011

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Thalassemia syndrome

Deferiprone (trade name Ferriprox) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Deferiprone is an orally bioavailable bidentate...

ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to iron, deferiprone is able to remove excess iron from the body. All the adverse effects of deferiprone are considered reversible, controllable and manageable. These include agranulocytosis with frequency of about 0.6%, neutropenia 6%, musculoskeletal and joint pains 15%, gastrointestinal complains 6% and zinc deficiency 1%.

METHYLAMINE

BSF23SJ79E

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

Methylammonium bromide

NDV5PY4944

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

METHYLAMINE HYDROCHLORIDE

M439EX322K

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1